AffiliationUniv Arizona, Coll Med, TREAT Program
MetadataShow full item record
PublisherWALTER DE GRUYTER GMBH
CitationHormone Molecular Biology and Clinical Investigation, Volume 33, Issue 1, 20170076, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2017-0076.
RightsCopyright © 2018 Walter de Gruyter GmbH, Berlin/Boston.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractBackground: Lipedema is a chronic disorder presenting in women during puberty or other times of hormonal change such as childbirth or menopause, characterized by symmetric enlargement of nodular, painful subcutaneous adipose tissue (fat) in the limbs, sparing the hands, feet and trunk. Healthcare providers underdiagnose or misdiagnose lipedema as obesity or lymphedema. Materials and methods: The benefits (friend) and negative aspects (foe) of lipedema were collected from published literature, discussions with women with lipedema, and institutional review board approved evaluation of medical charts of 46 women with lipedema. Results: Lipedema is a foe because lifestyle change does not reduce lipedema fat, the fat is painful, can become obese, causes gait and joint abnormalities, fatigue, lymphedema and psychosocial distress. Hypermobility associated with lipedema can exacerbate joint disease and aortic disease. In contrast, lipedema fat can be a friend as it is associated with relative reductions in obesity-related metabolic dysfunction. In new data collected, lipedema was associated with a low risk of diabetes (2%), dyslipidemia (11.7%) and hypertension (13%) despite an obese average body mass index (BMI) of 35.3 +/- 1.7 kg/m(2). Conclusion: Lipedema is a painful psychologically distressing fat disorder, more foe than friend especially due to associated obesity and lymphedema. More controlled studies are needed to study the mechanisms and treatments for lipedema.
Note12 month embargo; published online: 9 March 2018
VersionFinal published version
SponsorsLipedema Foundation; National Institute of General Medical Sciences of the National Institutes of Health [RL5GM118969, TL4GM 118971, UL1GM118970, 10.13039/100000002]